Human Pheromone Sciences Announces Second Quarter Results

Name	Symbol	Market	Type
ETF	BIT:EROX	Italy	Exchange Traded Fund

	Price Change	% Change	Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Traded	Last Trade
	-1.10	-0.35%	309.00	308.00	309.20	310.15	308.65	309.80	408	16:36:23

ETF (BIT:EROX)
Historical Stock Chart

From Jan 2020 to Jan 2025

Sales increase and loss reduced in quarter and six month periods SAN JOSE, Calif., Aug. 10 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC:EROX) (BULLETIN BOARD: EROX) ("HPS" or "the Company") today announced results for the second quarter ended June 30, 2006. Net sales of $184,000, represented a 40% increase from the sales of $131,000 in the prior year period, and resulted in a net loss of $156,000 ($.04 per share) as compared with a net loss of $248,000 ($.06 per share) for the same period of 2005. For the six month period, net sales grew by 75% to $450,000 from $257,000, and the loss was reduced by 58% to $226,000 from the $529,000 incurred in the first six months of the prior year. "The second quarter increase in net sales reflected particularly strong growth in our International markets, a result of increased sales to our distributor in the Far East. For the six months, net sales increased both domestically by 42% and 146% outside the United States. Sales for the first six months exceeded sales for the entire previous year of $414,000. While we are very pleased to see current customers increasing their purchases, attracting additional clients continues to be a focus for the current year," noted a Company spokesperson. Selling, general and administrative expense dropped approximately 21% in both the three and six month of 2006 as compared with the prior year periods, resulting in 37% improvement in net loss for the three months and a 57% reduction in the six moth loss, as compared with those periods in 2005." Human Pheromone Sciences, Inc. is a technology-based company, whose proof- of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at http://www.erox.com/. The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2005, and Form 10-QSB for the quarter ended June 30, 2006, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. HUMAN PHEROMONE SCIENCES, INC. Condensed Balance Sheets (Dollars in thousands) June 30, 2006 (unaudited) December 31, 2005 Assets Cash and cash equivalents $252 $452 Accounts receivable, net 52 11 Inventories, net 74 70 Other current assets 13 18 Property and equipment, net 5 8 Total $396 $559 Liabilities and shareholders' deficit Accounts payable $79 $21 Other current liabilities 107 119 Common stock 20,826 20,809 Accumulated deficit (20,616) (20,390) Total $396 $559 HUMAN PHEROMONE SCIENCES, INC. Condensed Statements of Operations (Unaudited) (Dollars in thousands, except per-share data) Three months Six months ended June 30, ended June 30, 2006 2005 2006 2005 Net revenue $184 $131 $450 $257 Cost of goods sold 58 17 111 58 Research and development 35 48 59 94 Selling, general and administrative 247 319 507 645 Loss from operations (156) (253) (227) (540) Other income - 5 1 11 Net loss $(156) $(248) $(226) $ (529) Loss per share - Basic and fully diluted: $(0.04) $(0 .06) $(0.05) $(0.13) Weighted average number of shares - Basic and fully diluted: 4,152 4,152 4,152 4,152 Net income (loss) per share is based on the weighted average number of common shares and common equivalents outstanding during each period. Certain common stock equivalents are excluded when their effect would be anti-dilutive. DATASOURCE: Human Pheromone Sciences, Inc. CONTACT: William P. Horgan, Chairman, CEO, or Gregory Fredrick, Chief Financial Officer, both of +1-408-938-3030, both of Human Pheromone Sciences, Inc. Web site: http://www.erox.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

EROX ETF